BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 2, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 13, 2006
View Archived Issues
Acorda’s Second Attempt At IPO Successful: $33M
Acorda Therapeutics Inc. priced a $33 million initial public offering Friday, selling 5.5 million common shares at $6 apiece. (BioWorld Today)
Read More
Private Placement Adding $27M To VaxGen’s Anthrax Drug Work
Read More
Deal Terms Reward Products: No Surprise From 2005 Trends
Read More
Black Box Warning Labels To Remain On All NSAIDs
Read More
After First Product Approval, BioMimetic Seeks $50M IPO
Read More
Clinic Roundup
Read More
Other News To Note
Read More